Ocuphire Pharma (OCUP) Stock Price, News & Analysis

Company Overview

Ocuphire Pharma, Inc., a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. The company offers Phentolamine Ophthalmic Solution for reversal of mydriasis, as well as is in Phase III clinical trials for presbyopia and dim light or night vision disturbances. Its lead retinal product candidate is APX3330, a small-molecule inhibitor of reduction oxidation effector factor-1 protein that has completed Phase II clinical trial for the treatment of diabetic retinopathy. The company also develops APX2009 and APX2014 that are preclinical product candidates for retina indications. The company was founded in 2018 and is headquartered in Farmington Hills, Michigan.

Key Stats

• Today's Range: N/A
• 50-Day Range: $1.17 to $1.46
• 52-Week Range: N/A
• Volume: 676,700 shs
• Average Volume: 171,840 shs
• Market Capitalization: $30.33 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $10.00
• Consensus Rating: Buy

OCUP Stock Analysis - Frequently Asked Questions

How were Ocuphire Pharma's earnings last quarter?

Ocuphire Pharma, Inc. (NASDAQ:OCUP) announced its quarterly earnings results on Friday, August, 11th. The company reported ($0.24) EPS for the quarter, missing the consensus estimate of ($0.23) by $0.01. The company earned $3.67 million during the quarter. Ocuphire Pharma had a negative trailing twelve-month return on equity of 30.19% and a negative net margin of 85.75%.

What other stocks do shareholders of Ocuphire Pharma own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Ocuphire Pharma investors own include NVIDIA (NVDA), Meta Platforms (META), Arista Networks (ANET), Broadcom (AVGO), ServiceNow (NOW), Novo Nordisk A/S (NVO) and e.l.f. Beauty (ELF).

Company Calendar

• Last Earnings: 8/11/2023
• Today: 8/29/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: N/A
• Current Symbol: NASDAQ:OCUP
• CIK: 1228627
• Web: www.ocuphire.com
• Phone: (248) 681-9815
• Fax: 240-268-5310
• Employees: 14
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Ocuphire Pharma: $10.00
• High Price Target: $10.00
• Low Price Target: $10.00
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 1 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.49)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$9.99 million
• Net Margins: -85.75%
• Pretax Margin: -85.68%
• Return on Equity: -30.19%
• Return on Assets: -27.55%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 10.68
• Quick Ratio: 10.68

Sales & Book Value

• Annual Sales: $16.45 million
• Price / Sales: 0.00
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.20 per share
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 25,924,000
• Free Float: 24,469,000
• Market Cap: $30.33 million
• Optionable: Optionable
• Beta: 0.20